Technical Comparison of Three Surgical Methods: Open, Semi-closure, and Primary Closure in the Treatment of Pilonidal Sinus

Background and Objective: Pilonidal sinus of the sacrum is a relatively common chronic infectious disease. Surgical management of pilonidal sinus is a challenging matter, and despite the different surgical techniques, the recurrence rate is still high. Materials and Methods: This double-blind clinical trial study was conducted on 60 patients with pilonidal sinus (2023). These patients underwent surgery randomly and based on the available sampling method in three methods: open, semi-closure, and primary closure. Recovery time and intraoperative bleeding were recorded. The McGill Pain Questionnaire was used to evaluate postoperative pain, and the Southampton scale was employed to assess infection and secretions. Results: The recovery time was longer in the open method than in the closure and semi-closure methods (P=0.001). However, this difference did not exist between the closure and semi-closure methods (P=0.402). There were two cases of recurrence in the closed method, while no recurrence was observed in the open and semi-closure methods. The patients undergoing the closure surgical method experienced less bleeding postoperatively (P=0.002). No significant relationship was found between surgical method and infection (P=0.189). There was no significant difference in the intensity of pain experienced by patients after the operation (P=0.789). Conclusion: For the treatment of pilonidal sinus, primary surgical closure is not recommended due to recurrences, despite the shorter recovery time and less bleeding. The semi-closure surgical method seems to be safer than the open and primary closure methods

Application of Nanoliposomes Containing Nisin and Crocin in Milk

Purpose: This study aimed to investigate the effects of nanoliposomes containing crocin and nisin in milk samples as a food model. Therefore, three formulations were prepared and compared, including (1) milk samples containing free nisin and crocin, (2) samples with nanoliposomes containing nisin and crocin, and (3) nisin and crocin-loaded nanoliposomes coated with chitosan. Methods: In order to find the optimum amount of both bioactives within nanoliposomes, analyses of size, polydispersity index (PDI), zeta potential, and encapsulation efficiency were accomplished. Then, the best formulated nanoliposome was evaluated and compared with a solution containing free bioactives and nanoliposomes coated with chitosan using other experiments, including antioxidant and antibacterial activities, viscosity, colorimetric and bacterial growth. Results: The best nanoliposomal system based on the factors of size, PDI, zeta potential, and encapsulation efficiency was related for the nanocarrier with 4 mg crocin, 4.5 mg nisin, and 40 mg lecithin. Based on the results obtained, both nanoliposome (a*=5.41) and chitosancoated nanoliposome (a*=5.09) solutions could significantly (P<0.05) reduce the redness of milk induced by free bioactives (a*=12.32). However, viscosity of milk in chitosan-coated nanoliposome solution was found to be higher (3.42 cP) than other formulations (viscosity of samples with free bioactives was 1.65 cP and viscosity of samples containing nanoliposome was 1.71 cP). In addition, chitosan-coated nanoliposomes could inhibit the growth of Listeria monocytogenes stronger than other samples. Conclusion: Encapsulation of nisin and crocin in nanoliposomes showed promising results for preserving food safety and quality

Rituximab therapy improves recalcitrant Pemphigus vulgaris

Pemphigus is a severe life-threatening blistering disease associated with autoantibodies against cell adhesion proteins desmogleins 1 and 3. Patients with severe pemphigus commonly show high rates of relapse after conventional immunosuppressive therapy. The newly developed drug Rituximab showed impressing promises in the treatment of refractory pemphigus vulgaris (PV). In the present study the efficacy of a single course rituximab therapy in the treatment of PV was investigated. Eighteen patients with severe recalcitrant PV were recruited to this study. Pemphigus disease activity index (PDAI), anti-desmoglein 1 and anti-desmoglein 3 antibody titers, and percent of CD20 positive cells were measured at baseline, 10 ± 1, and 22 ± 2 weeks after rituximab therapy. Rituximab was given intravenously at dose 375 mg/m2 once weekly for 4 weeks. Rituximab therapy caused a dramatic reduction in the PDAI, accompanied by decreases in anti-desmoglein 1 and anti-desmoglein 3 antibody titers over the follow-up course. The B-cell population decreased at the first follow-up, but returned to its baseline levels at the second follow-up. Rituximab therapy decreased the dose of immunosuppressive drugs required to control the disease. It seems that the rituximab may be effective and safe for treatment of refractory PV

The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019

Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe

Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017

Correction:Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.Peer reviewe

The electrical transition temperature and magnetoresistance prediction of LaSr2Mn2O7 bilayered manganite

In this paper, the resistivity of bilayer manganite LaSr2Mn2O7 around the metal–insulator-like transition was systematically calculated as a function of temperature and applied magnetic field. A typical mathematical function (Gauss function) was used for fitting the experimental data. The theoretical values simulated in this work such as – metal–insulator transition temperature (Tp) and maximum resistivity (ρmax) showed promising agreement with the experimental data. Keywords: Bilayered manganite, Magneto-resistance, Resistivity, Fittin

Numerical modeling of molecular diffusion and convection effects during gas injection into naturally fractured oil reservoirs

Gas injection into a naturally fractured oil reservoir keeps the reservoir pressure and increments the initial recovery from the reservoir. The main aim of this work was to develop a numerical model to calculate the mass transfer (molecular diffusion and convection) between a gas injected in the fracture and residual fluid (gas and oil) in a matrix block. The dual continuum model is applied to describe flow behaviour and fluid recovery in porous media. Finally, the model is validated by comparing the outcomes with the results of two experimental works available in the literature. The mathematical model results are in agreement with the laboratory data including recovery of each component, saturation profile, and the pressure gradient between matrix and fracture. Modeling results show that after 25 days of N2 injection, the lighter and heavier components (C1 and C5) are recovered about 51% and 39%, respectively. These amounts for CO2 injection are 49% and 27%. It is found that the convection mechanism has a great effect on preventing the pressure drop of the reservoir during injection operations. In the nitrogen injection, without considering the convection, after 30 days, the matrix pressure reaches 1320 Psi from 1479 Psi but after 30 days, considering the convection, the pressure reaches 1473 Psi from 1479 Psi

Seroprevalence of anti-helicobacter pylori antibodies in hepatitis B and C patients with cirrhosis: a case-control study

&lt;strong&gt;BACKGROUND&lt;/strong&gt;: Cirrhosis is terminal stage of many chronic liver diseases like hepatitis C and hepatitis B. In some studies the role of helicobacter pylori has been demonstrated in progress of cirrhosis and its complications, but none of the previous studies has investigated the role of socioeconomic conditions of patients in childhood period in this issue.&lt;br /&gt; &lt;strong&gt;METHODS&lt;/strong&gt;: In a case-control study, we examined 100 cirrhotic patients due to hepatitis (49 hepatitis B and 51 hepatitis C patients) and 101 socioeconomically matched healthy controls presenting to Taleghani Hospital for IgG antibody to helicobacter pylori.&lt;br /&gt; &lt;strong&gt;RESULTS&lt;/strong&gt;: IgG antibody to helicobacter pylori was present in 73% of cirrhotic patients and 52% of control group (P&amp;lt;0.003). Odds ratio for the presence of IgG antibody to helicobacter pylori in cirrhotic men comparing with healthy men was 3.2 (95%CI: 1.4-7.4).&lt;br /&gt; &lt;strong&gt;CONCLUSIONS&lt;/strong&gt;: The relative frequency of IgG antibody to helicobacter pylori found to be higher in cirrhotic patients than in controls with regard to socioeconomic condition in childhood.&lt;br /&gt; &lt;strong&gt;KEY WORDS&lt;/strong&gt;: Cirrhosis, hepatitis C, hepatitis B, helicobacter pylori, liver disease